Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD)

Trends in Genetics

Volumn 31, Issue 5, 2015, Pages 263-273

  Lattante, Serena ^a,b,c   Ciura, Sorana ^a   Rouleau, Guy A ^d   Kabashi, Edor ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; TAR DNA BINDING PROTEIN; VALOSIN CONTAINING PROTEIN;

ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL FEATURE; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEREDITY; HUMAN; LINKAGE ANALYSIS; MOTONEURON; MUTATION RATE; NERVE DEGENERATION; NONHUMAN; ONSET AGE; PENETRANCE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; INHERITANCE; RISK FACTOR; TRANSLATIONAL RESEARCH;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; FRONTOTEMPORAL DEMENTIA; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INHERITANCE PATTERNS; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84928769147     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2015.03.005     Document Type: Review

References (177)

1. Nelson L.M. Epidemiology of ALS. Clin. Neurosci. 1995-1996, 3:327-331.
2. Chiò A., et al. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009, 72:725-731.
3. Harvey R.J., et al. The prevalence and causes of dementia in people under the age of 65 years. J. Neurol. Neurosurg. Psychiatry 2003, 74:1206-1209.
4. Ratnavalli E., et al. The prevalence of frontotemporal dementia. Neurology 2002, 58:1615-1621.
5. Burrell J.R., et al. Motor neuron dysfunction in frontotemporal dementia. Brain 2011, 134:2582-2594.
6. Lomen-Hoerth C., et al. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
7. Ringholz G.M., et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005, 65:586-590.
8. Neumann M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
9. Morita M., et al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006, 66:839-844.
10. Vance C., et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006, 129:868-876.
11. DeJesus-Hernandez M., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
12. Renton A.E., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
13. Charcot J., Joffroy A. Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et des faisceaux antéro-latéraux de la moelle épinière. Arch. Physiol. Neurol. Pathol. 1869, 2:744.
14. Siddique T., et al. Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N. Engl. J. Med. 1991, 324:1381-1384.
15. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
16. van Es M.A., et al. Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2010, 81:562-566.
17. Millecamps S., et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J. Med. Genet. 2010, 47:554-560.
18. Chiò A., et al. Extensive genetics of ALS: a population-based study in Italy. Neurology 2012, 79:1983-1989.
19. Chiò A., et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J. Neurol. Neurosurg. Psychiatry 2014, 85:478-485.
20. Lattante S., et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 2012, 79:66-72.
21. Andersen P.M., Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. Nat. Rev. Neurol. 2011, 7:603-615.
22. Leblond C.S., et al. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 2014, 262PB:91-101.
23. Abel O., et al. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012, 33:1345-1351.
24. Lill C.M., et al. Keeping up with genetic discoveries in amyotrophic lateral sclerosis: the ALSoD and ALSGene databases. Amyotroph. Lateral Scler. 2011, 12:238-249.
25. Cruts M., et al. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012, 33:1340-1344.
26. Stenson P.D., et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 2003, 21:577-581.
27. Gitcho M.A., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008, 63:535-538.
28. Kabashi E. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40:572-574.
29. Sreedharan J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
30. Kwiatkowski T.J., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
31. Vance C., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:1208-1211.
32. Lattante S., et al. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum. Mutat. 2013, 34:812-826.
33. Ling S.C., et al. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013, 79:416-438.
34. Broustal O., et al. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J. Alzheimers Dis. 2010, 22:765-769.
35. Van Langenhove T., et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 2010, 74:366-371.
36. Yan J., et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 2010, 75:807-814.
37. Valdmanis P.N., et al. Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch. Neurol. 2007, 64:240-245.
38. Le Ber I., et al. Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 2009, 72:1669-1676.
39. Boxer A.L., et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J. Neurol. Neurosurg. Psychiatry 2010, 82:196-203.
40. Laaksovirta H., et al. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 2010, 9:978-985.
41. Shatunov A., et al. Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 2010, 9:986-994.
42. Luty A.A., et al. Pedigree with frontotemporal lobar degeneration-motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol. 2008, 8:32.
43. Majounie E., et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012, 11:323-330.
44. van der Zee J., et al. A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum. Mutat. 2013, 34:363-373.
45. Byrne S., et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2013, 74:699-708.
46. Elamin M., et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 2013, 80:1590-1597.
47. Montuschi A. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. J. Neurol. Neurosurg. Psychiatry 2015, 86:168-173.
48. Johnson J.O., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68:857-864.
49. DeJesus-Hernandez M., et al. Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology 2011, 77:1102-1103.
50. Deng H.X., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
51. Koppers M., et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:837.
52. Tiloca C., et al. Mutational analysis of VCP gene in familial amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:630.
53. Williams K.L., et al. Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:1488.
54. Abramzon Y., et al. Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:2231.
55. Miller J.W., et al. Mutation analysis of VCP in British familial and sporadic amyotrophic lateral sclerosis patients. Neurobiol. Aging 2012, 33:2721.
56. Zou Z.Y., et al. Screening of VCP mutations in Chinese amyotrophic lateral sclerosis patients. Neurobiol. Aging 2013, 34:1519.
57. Daoud H., et al. UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:2230.
58. Millecamps S., et al. Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:839.
59. Synofzik M., et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol. Aging 2012, 33:2949.
60. van Doormaal P.T., et al. UBQLN2 in familial amyotrophic lateral sclerosis in The Netherlands. Neurobiol. Aging 2012, 33:2233.
61. Williams K.L., et al. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:2527.
62. Dillen L., et al. Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. Neurobiol. Aging 2013, 34:1711.
63. Gellera C., et al. Ubiquilin 2 mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 2013, 84:183-187.
64. Lattante S., et al. Screening UBQLN-2 in French frontotemporal lobar degeneration and frontotemporal lobar degeneration-amyotrophic lateral sclerosis patients. Neurobiol. Aging 2013, 34:2078.
65. Kim H.J., et al. Mutations in UBQLN2 and SIGMAR1 genes are rare in Korean patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2014, 35:1957.
66. McLaughlin R.L., et al. UBQLN2 mutations are not a frequent cause of amyotrophic lateral sclerosis in Ireland. Neurobiol. Aging 2014, 35:267.
67. Fecto F., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:1440-1446.
68. Rubino E., et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012, 79:1556-1562.
69. Hirano M., et al. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology 2013, 80:458-463.
70. Shimizu H., et al. Sporadic ALS with compound heterozygous mutations in the SQSTM1 gene. Acta Neuropathol. 2013, 126:453-459.
71. Le Ber I., et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 2013, 70:1403-1410.
72. Teyssou E., et al. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol. 2013, 125:511-522.
73. Chen Y., et al. SQSTM1 mutations in Han Chinese populations with sporadic amyotrophic lateral sclerosis. Neurobiol. Aging 2014, 35:726.
74. Kwok C.T., et al. Sequestosome-1 (SQSTM1) sequence variants in ALS cases in the UK: prevalence and coexistence of SQSTM1 mutations in ALS kindred with PDB. Eur. J. Hum. Genet. 2014, 22:492-496.
75. van der Zee J., et al. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol. 2014, 128:397-410.
76. Bannwarth S., et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 2014, 137:2329-2345.
77. Müller K., et al. Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain 2014, 137:e309.
78. Bannwarth S., et al. Reply: Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain 2014, 137:e310.
79. Chaussenot A., et al. Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. Neurobiol. Aging 2014, 35:2884.
80. Johnson J.O., et al. Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain 2014, 137:e311.
81. Renton A.E., et al. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17:17-23.
82. Coppola G., et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum. Mol. Genet. 2012, 21:3500-3512.
83. Lee S.E., et al. Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2013, 27:302-309.
84. Van Hoecke A., et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 2012, 18:1418-1422.
85. Fecto F., Siddique T. Making connections: pathology and genetics link amyotrophic lateral sclerosis with frontotemporal lobe dementia. J. Mol. Neurosci. 2011, 45:663-675.
86. Seelaar H., et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J. Neurol. Neurosurg. Psychiatry 2011, 82:476-486.
87. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14:248-264.
88. Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013, 9:617-628.
89. Rademakers R., et al. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 2012, 8:423-434.
90. van Es M.A., et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 2009, 41:1083-1087.
91. Diekstra F.P., et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:630.
92. Chiò A., et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol. Aging 2013, 34:357.
93. Diekstra F.P., et al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. Ann. Neurol. 2014, 76:120-133.
94. Luty A.A., et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann. Neurol. 2010, 68:639-649.
95. Belzil V.V., et al. Genetic analysis of SIGMAR1 as a cause of familial ALS with dementia. Eur. J. Hum. Genet. 2013, 21:237-239.
96. Saif A., et al. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 2011, 70:913-919.
97. Kim H.J. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013, 495:467-473.
98. Calini D., et al. Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2013, 34:2695.
99. Le Ber I., et al. hnRNPA2B1 and hnRNPA1 mutations are rare in patients with 'multisystem proteinopathy' and frontotemporal lobar degeneration phenotypes. Neurobiol. Aging 2014, 35:934.
100. Seelen M., et al. No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiol. Aging 2014, 35:1956.
101. Xi Z., et al. Identical twins with the C9orf72 repeat expansion are discordant for ALS. Neurology 2014, 83:1476-1478.
102. Özoğuz A., et al. The distinct genetic pattern of ALS in Turkey and novel mutations. Neurobiol. Aging 2015, 36. 1764.e9-e18.
103. Kim E.J., et al. Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia. Neurobiol. Aging 2014, 35:1213.
104. García-Redondo A., et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum. Mutat. 2013, 34:79-82.
105. Ogaki K., et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2012, 33:2527.
106. Elden A.C., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466:1069-1075.
107. van Blitterswijk M., et al. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol. Aging 2014, 35:2421.
108. Lattante S., et al. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology 2014, 83:990-995.
109. Chiò A., et al. ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. J. Neurol. Neurosurg. Psychiatry 2012, 83:730-733.
110. Cooper-Knock J., et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012, 135:751-764.
111. Millecamps S., et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J. Med. Genet. 2012, 49:258-263.
112. Ratti A., et al. C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. Neurobiol. Aging 2012, 33:2528.
113. van Blitterswijk M., et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012, 21:3776-3784.
114. Borghero G., et al. Genetic architecture of ALS in Sardinia. Neurobiol. Aging 2014, 35:2882.
115. Kaivorinne A.L., et al. Novel TARDBP sequence variant and C9ORF72 repeat expansion in a family with frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 2014, 28:190-193.
116. Origone P., et al. Neuroimaging features in C9orf72 and TARDBP double mutation with FTD phenotype. Neurocase 2014, Published online August 20, 2014/. 10.1080/13554794.2014.951057.
117. Ferrari R., et al. Screening for C9ORF72 repeat expansion in FTLD. Neurobiol. Aging 2012, 33:1850.
118. van Blitterswijk M., et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 2013, 81:1332-1341.
119. Mignarri A., et al. Double trouble? Progranulin mutation and C9ORF72 repeat expansion in a case of primary non-fluent aphasia. J. Neurol. Sci. 2014, 341:176-178.
120. Lashley T., et al. A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. Neuropathol. Appl. Neurobiol. 2014, 40:502-513.
121. Kenna K.P., et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. J. Med. Genet. 2013, 50:776-783.
122. Luigetti M., et al. SOD1 G93D sporadic amyotrophic lateral sclerosis (SALS) patient with rapid progression and concomitant novel ANG variant. Neurobiol. Aging 2011, 32:1924.
123. Greenway M.J., et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. 2006, 38:411-413.
124. Cady J., et al. ALS onset is influenced by the burden of rare variants in known ALS genes. Ann. Neurol. 2015, 77:100-113.
125. Dimos J.T., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
126. Burkhardt M.F., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 2013, 56:355-364.
127. Hargus G., et al. Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. Acta Neuropathol. 2014, 127:151-173.
128. Almeida S., et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013, 126:385-399.
129. Donnelly C.J., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 2013, 80:415-428.
130. Egawa N., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012, 4:145ra104.
131. Kabashi E., et al. Zebrafish models for the functional genomics of neurogenetic disorders. Biochim. Biophys. Acta 2011, 1812:335-345.
132. Lanson N.A., Pandey U.B. FUS-related proteinopathies: lessons from animal models. Brain Res. 2012, 1462:44-60.
133. Tsao W., et al. Rodent models of TDP-43: recent advances. Brain Res. 2012, 1462:26-39.
134. Babin P.J., et al. Zebrafish models of human motor neuron diseases: advantages and limitations. Prog. Neurobiol. 2014, 118:36-58.
135. Patten S.A., et al. Fishing for causes and cures of motor neuron disorders. Dis. Model Mech. 2014, 7:799-809.
136. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
137. Cleveland D.W., et al. Mechanisms of selective motor neuron death in transgenic mouse models of motor neuron disease. Neurology 1996, 47:S54-S56.
138. Perrin S. Preclinical research: make mouse studies work. Nature 2014, 507:423-425.
139. Ciura S., et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 2013, 74:180-187.
140. McGown A., et al. Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Ann. Neurol. 2013, 73:246-258.
141. Schmid B., et al. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4986-4991.
142. Da Costa M.M., et al. A new zebrafish model produced by TILLING of SOD1-related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis. Model Mech. 2014, 7:73-81.
143. Lattante S., et al. Sqstm1 knock-down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum. Mol. Genet. 2015, 24:1682-1690.
144. Van Damme P., et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011, 76:2066-2072.
145. Ross O.A., et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum. Mol. Genet. 2011, 20:3207-3212.
146. Corrado L., et al. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum. Genet. 2011, 130:575-580.
147. Daoud H., et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:739-742.
148. Chen Y., et al. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2011, 32:1925.
149. Gispert S., et al. The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol. Dis. 2012, 45:356-361.
150. Gellera C., et al. ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol. Aging 2012, 33:1847.
151. Van Langenhove T., et al. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol. Aging 2012, 33:1004.
152. Lahut S., et al. ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS ONE 2012, 7:e42956.
153. Liu X., et al. ATXN2 CAG repeat expansions increase the risk for Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2013, 34:2236.
154. Wang M.D., et al. Intermediate CAG repeat expansion in the ATXN2 gene is a unique genetic risk factor for ALS - a systematic review and meta-analysis of observational studies. PLoS ONE 2014, 9:e105534.
155. Neuenschwander A.G., et al. Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a meta-analysis. JAMA Neurol. 2014, 71:1529-1534.
156. Lu H.P., et al. Intermediate-length polyglutamine in ATXN2 is a possible risk factor among Eastern Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 2015, 36:1603.
157. Lee T., et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum. Mol. Genet. 2011, 20:1697-1700.
158. Sorari G., et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 2011, 76:2030-2031.
159. Conforti F.L., et al. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology 2012, 79:2315-2320.
160. Phillips P.C. Epistasis - the essential role of gene interactions in the structure and evolution of genetic systems. Nat. Rev. Genet. 2008, 9:855-867.
161. Kabashi E., et al. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet. 2011, 7:e1002214.
162. Mackenzie I.R., et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007, 61:427-434.
163. Barmada S.J., et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 2014, 10:677-685.
164. Farg M.A., et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 2014, 23:3579-3595.
165. King O.D., et al. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012, 1462:61-80.
166. Van Deerlin V.M., et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 2010, 42:234-239.
167. Vass R., et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011, 121:373-380.
168. van der Zee J., et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 2011, 134:808-815.
169. Gallagher M.D., et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014, 127:407-418.
170. van Blitterswijk M., et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol. 2014, 127:397-406.
171. Lattante S., et al. Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neurobiol. Aging 2014, 35:2658.
172. Vaccaro A., et al. Methylene blue protects against TDP-43 and FUS neuronal toxicity in C. elegans and D. rerio. PLoS ONE 2012, 7:e42117.
173. Vaccaro A., et al. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol. Dis. 2013, 55:64-75.
174. Armstrong G.A., Drapeau P. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. J. Neurosci. 2013, 33:1741-1752.
175. Fogh I., et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014, 23:2220-2231.
176. Smith B.N., et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 2014, 84:324-331.
177. Cirulli E.T., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015, 347:1436-1441.